Study of AWT020 for advanced solid tumors and lymphoma
Part of Cancer clinical trials.
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (carcinoma or sarcoma) or lymphoma that has spread or can't be removed, and standard treatments have stopped working or aren't an option.
- You are age 18 or older.
- You are able to take care of yourself (fully active or limited only in strenuous physical activity).
- Your major organs (like liver, kidneys, bone marrow) are working well enough to handle the study drug.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
This trial tests a new drug (WTX212A) alone or with radiation therapy for people with advanced solid tumors. It aims to see if the treatment is safe and how well it works.
This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.
This trial tests a new drug called LAT010 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.